COO
COOPER COMPANIES, INC.Evidence as of 2026-09-02Overview · COOPER COMPANIES, INC.
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocul…
Management team
- Mr. Nicholas S. Khadder J.D. · VP, General Counsel & Corporate SecretaryFind on LinkedIn
- Mr. Gerard H. Warner III · President of CooperVision, Inc.Find on LinkedIn
- Ms. Holly R. Sheffield · President of CooperSurgical, Inc.Find on LinkedIn
- Mr. Daniel G. McBride Esq. · Executive VP & COOFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
−0.3 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
The desk records revenue of $1,022,100,000 in fiscal Q1 2026 (fiscal quarter ended 2026-03-02) and $1,081,500,000 in fiscal Q2 2026 (fiscal quarter ended 2026-06-01). Gross profit was $695,200,000 in fiscal Q1 2026 and $735,400,000 in fiscal Q2 2026, implying gross margins of roughly 67.99% and 68.03% respectively.
Net income swung from a positive $130,800,000 in fiscal Q1 2026 to a loss of $-77,900,000 in fiscal Q2 2026 (this claim was weakened in debate). Weighted-average diluted shares declined from 201,200,000 in fiscal Q1 2026 to 195,000,000 in fiscal Q2 2026, and reported shares outstanding fell from 199,512,504 as of 2025-05-26 to 195,030,630 as of 2026-06-01, consistent with active repurchases (payments for repurchase were $92,500,000 in fiscal Q1 2026). Valuation and market metrics show a price-to-FCF of 38.81, EV/EBITDA of 16.64, PE of 58.22, elevated short-term volatility (30‑day annualized +22.7%), material three‑year drawdown (-47.0% max, current -37.7%), price below the 50‑ and 200‑day SMAs (-4.5% and -5.6%), and low market sensitivity (beta 0.53, correlation 0.24). The evidence balance is Mixed ( -0.3 of a possible +2; was -0.3 before debate), with confidence high.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Revenue was $1,022,100,000 in fiscal Q1 2026 (2024-11-01 to 2025-01-31, 3mo) and $1,081,500,000 in fiscal Q2 2026 (2026-02-01 to 2026-04-30, 3mo).
XBRL companyfacts · 0001628280-26-015620Gross profit was $695,200,000 in fiscal Q1 2026 (2024-11-01 to 2025-01-31, 3mo) and $735,400,000 in fiscal Q2 2026 (2026-02-01 to 2026-04-30, 3mo), implying gross margins of ~67.99% in Q1 2026 (695,200,000 / 1,022,100,000) and ~68.03% in Q2 2026 (735,400,000 / 1,081,500,000).
XBRL companyfacts · 0001628280-26-015620Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Nothing in this slice of the evidence rose to a claim — a quiet read, which itself is information.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
Three-month momentum is +16.5% while six-month momentum is -16.9%, producing a six-month momentum percentile at the 11th percentile of the research universe.
Moneyta signal set · 2026-09-01weakened in debateTwelve-month-minus-one-month momentum (momentum_12_1) is +5.0% with a rank at the 40th percentile of the research universe.
Moneyta signal set · 2026-09-01weakened in debateReads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
As of 2026-09-02, COO is a constituent of the IVV ETF with a weight of 0.02% of that fund.
ETF constituents · market dataThe most recently reported 13F quarter, as of 2023-12-31, shows a single institutional holder (Advisors Asset Management, Inc.) with a reported position value of $2.8M.
13F holdings · 1 filers · as of 2023-12-31weakened in debateReads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Wellington Management Group LLP acquired 103,044 shares of The Cooper Companies, Inc., increasing its stake by 3.1% in the second quarter, per a Form 13F filing.
News · thelincolnianonline.com · 2026-08-31Multiple institutional investors were reported as initiating or adding to positions in The Cooper Companies, Inc. in the second quarter, including Sanctuary Advisors LLC (29,478 shares, ~$2,114,000), Bluefin Capital Management LLC (12,500 shares), Callan Family Office LLC (7,974 shares), and Expect Equity LLC (42,050 shares).
News · thelincolnianonline.com · 2026-08-27Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
No insider transactions on file in the trailing 180 days.
Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The model-implied free cash flow (FCF) growth rate today's price would justify is 25.97% per year (implied_growth = 0.2597).
Valuation inputs · SEC XBRL + stored EOD closeTrailing twelve-month free cash flow (FCF) is $348,100,000 and FCF per share is $1.7851.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
Several company-specific fundamentals and capital-allocation signals together paint a favorable operational and balance-sheet picture. Revenue and gross profit rose quarter-over-quarter while gross margins remained near 68% (fundamentals-0, fundamentals-1), and the company simultaneously reduced diluted shares and executed meaningful repurchases (fundamentals-3, fundamentals-4), concentrating reported free cash flow per share (valuation-1). Reported long-term debt declined across balance dates (fundamentals-5), and institutional buying activity appears in recent 13F/news filings (news-0, news-1, news-2, news-4). These points, together with a moderate EV/EBITDA (valuation-3) and low market beta/correlation to SPY (market-5), support a constructive interpretation of the underlying business strength that mitigates some market-technical and valuation headwinds.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.38
26 surviving claims rest on 11 distinct sources; the heaviest analyst carries 23% of them, and 90% of what the desk raised survived the debate.
The surviving read is moderately robust: 26 claims rely on 11 distinct sources, so findings are not concentrated in a single document but do lean on a relatively small set of inputs. The largest analyst carrying 23% of the surviving claims and a 90% survival rate from the desk debate imply the conclusions had substantial internal support, but analyst concentration and the modest source count mean individual new documents or a key analyst correction could materially change the picture.
Peer context · computed, not argued
12-1 momentum ranks 3rd of 3 in Medical Instruments & Supplies (as of 2026-09-01).
90-day volatility ranks 3rd of 3 in Medical Instruments & Supplies (as of 2026-09-01).
dividend yield ranks 3rd of 3 in Medical Instruments & Supplies (as of 2026-09-01).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
13 filings· 1 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer+0.7 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash−0.6 to the score
2 holdings records
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis−1.0 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on COO Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.